Thymosin Alpha-1 vs TB-500 for dogs
The short answer
The names cause genuine confusion — both are thymosins — but they are unrelated in function. Thymosin alpha-1 is an immune modulator with human regulatory approval outside the United States and the strongest safety record on this site. TB-500 is a thymosin beta-4 fragment studied for tissue repair, with a firm cancer contraindication. In a dog with cancer this distinction is decisive: thymosin alpha-1 is one of the few compounds here that published data suggests may be appropriate in that setting, while TB-500 is specifically contraindicated. They are not substitutes for one another in any context.
Side by side
| Thymosin Alpha-1 | TB-500 | |
|---|---|---|
| Evidence grade | Good evidence | Emerging evidence |
| Function | Immune modulation | Tissue repair and cell migration |
| Regulatory status | Approved as Zadaxin for human use outside the US; not FDA-approved | Research compound; banned in competitive racing |
| Cancer setting | Investigated as an oncology adjunct | Contraindicated with active cancer |
| Evidence grade | Good | Emerging |
| Full profile | Thymosin Alpha-1 for dogs | TB-500 for dogs |
Safety at a glance
Thymosin Alpha-1
Thymosin alpha-1 has the most established safety profile of anything covered here, having been approved for human use outside the United States for decades with no cumulative toxicity reported. It is also notable as an exception to the cancer contraindication that applies to most growth-promoting peptides — published data suggests it may support immune surveillance without appearing to promote tumour growth. The honest limitation is that essentially all of that evidence is human; no canine clinical trials exist.
Is Thymosin Alpha-1 safe for dogs? →TB-500
TB-500 is generally well tolerated in the veterinary literature, with injection-site swelling the most common observation. The decisive safety question is not tolerance but cancer status: because the compound is associated with promoting new blood vessel growth and cell migration, it is contraindicated in dogs with active or suspected malignancy. Screening before starting is not optional. It is also banned in competitive racing and is detectable on testing.
Is TB-500 safe for dogs? →Common questions
Which is better for dogs, Thymosin Alpha-1 or TB-500?+
The names cause genuine confusion — both are thymosins — but they are unrelated in function. Thymosin alpha-1 is an immune modulator with human regulatory approval outside the United States and the strongest safety record on this site. TB-500 is a thymosin beta-4 fragment studied for tissue repair, with a firm cancer contraindication. In a dog with cancer this distinction is decisive: thymosin alpha-1 is one of the few compounds here that published data suggests may be appropriate in that setting, while TB-500 is specifically contraindicated. They are not substitutes for one another in any context.
Can Thymosin Alpha-1 and TB-500 be used together in dogs?+
Combined protocols using both compounds appear in the literature, and they are more often studied together than as alternatives. Any combination increases the difficulty of attributing an adverse effect to a specific compound, so combining should be a deliberate decision made with your veterinarian rather than a default.
Which has better evidence in dogs, Thymosin Alpha-1 or TB-500?+
Thymosin Alpha-1 is graded good evidence with 5 cited studies; TB-500 is graded emerging evidence with 5 cited studies. Grades reflect the strength of published literature rather than an opinion about efficacy.
References
- 1.King R, Tuthill C Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and Hormones, 2016. PMID 27450734
- 2.Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology, 2020. PMID 33362999
- 3.Wei Y, Zhang J, Yan X, et al. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International Immunopharmacology, 2023. PMID 36812669
- 4.Guo Y, Chang H, Li J, et al. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway. Apoptosis, 2015. PMID 26002438
- 5.Wang F, Yu T, Zheng H, Lao X Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life. Scientific Reports, 2018. PMID 30120362
- 6.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
- 7.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 8.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 9.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
- 10.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.